Document 0938 DOCN M9540938 TI Vaccination of rabbits with recombinant vaccinia virus carrying the envelope gene of human T-cell lymphotropic virus type I. DT 9504 AU Hakoda E; Machida H; Tanaka Y; Morishita N; Sawada T; Shida H; Hoshino H; Miyoshi I; Department of Medicine, Kochi Medical School, Japan. SO Int J Cancer. 1995 Feb 8;60(4):567-70. Unique Identifier : AIDSLINE MED/95130294 AB Two groups of 3 rabbits each were immunized with either recombinant vaccinia virus, WR-SFB5env, carrying the human T-cell lymphotropic virus type I (HTLV-I) env gene at the site of the hemagglutinin gene of the WR strain, or control vaccinia virus, HA-WR, lacking the functional hemagglutinin gene. All 6 rabbits responded with anti-vaccinia virus antibodies. WR-SFB5env elicited anti-HTLV-I env antibodies but no vesicular stomatitis virus (HTLV-I) pseudotype neutralizing antibodies in all 3 rabbits. After 10 weeks, the animals were challenged by transfusion of blood from an HTLV-I-infected rabbit. Two of the 3 vaccinated rabbits and all 3 control rabbits became infected with HTLV-I, as indicated by seroconversion and detection of HTLV-I proviral sequences by polymerase chain reaction. The rabbit that had been protected from initial challenge became infected with HTLV-I upon rechallenge 12 weeks after the first challenge. In view of the proven prophylactic effect of passive immunization against HTLV-I, our vaccine trial failed because WR-SFB5env was incapable of inducing neutralizing antibodies against HTLV-I in the immunized animals. It remains to be studied whether cell-mediated immunity such as antibody-dependent cellular cytotoxicity was involved in the temporary protection of I vaccinated rabbit. DE Animal Blotting, Western Drug Screening Genes, env/IMMUNOLOGY HTLV-I/*GENETICS/IMMUNOLOGY HTLV-I Antibodies/*BIOSYNTHESIS/BLOOD HTLV-I Infections/*PREVENTION & CONTROL Neutralization Tests Polymerase Chain Reaction Rabbits Support, Non-U.S. Gov't *Vaccines, Synthetic Vaccinia Virus/IMMUNOLOGY Vesicular Stomatitis-Indiana Virus/IMMUNOLOGY *Viral Vaccines JOURNAL ARTICLE SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).